D'Amico AV - Search Results

1

Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate.

D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, Steigler A, Chen MH. D'Amico AV, et al. Cancer. 2007 May 15;109(10):2004-10. doi: 10.1002/cncr.22628. Cancer. 2007. PMID: 17397033 Free article.

2

The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.

D'Amico AV, Whittington R, Schnall M, Malkowicz SB, Tomaszewski JE, Schultz D, Wein A. D'Amico AV, et al. Cancer. 1995 May 1;75(9):2368-72. doi: 10.1002/1097-0142(19950501)75:9<2368::aid-cncr2820750929>3.0.co;2-#. Cancer. 1995. PMID: 7536124

3

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer.

D'Amico AV, Hanks GE. D'Amico AV, et al. Cancer. 1993 Nov 1;72(9):2638-43. doi: 10.1002/1097-0142(19931101)72:9<2638::aid-cncr2820720919>3.0.co;2-n. Cancer. 1993. PMID: 7691393

4

Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy.

D'Amico AV, Propert KJ. D'Amico AV, et al. Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):273-9. doi: 10.1016/0360-3016(95)02389-5. Int J Radiat Oncol Biol Phys. 1996. PMID: 8635933

5

What is the optimal patient selection for combined androgen ablative and radiation therapy? The role of combined modality staging.

D'Amico AV. D'Amico AV. Hematol Oncol Clin North Am. 1996 Jun;10(3):643-51. doi: 10.1016/s0889-8588(05)70358-0. Hematol Oncol Clin North Am. 1996. PMID: 8773502 Review.

6

Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage.

D'Amico AV, Chang H, Holupka E, Renshaw A, Desjarden A, Chen M, Loughlin KR, Richie JP. D'Amico AV, et al. Urology. 1997 Mar;49(3):385-91. doi: 10.1016/S0090-4295(96)00509-2. Urology. 1997. PMID: 9123703

7

Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients.

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. D'Amico AV, et al. Cancer J Sci Am. 1996 Nov-Dec;2(6):343-50. Cancer J Sci Am. 1996. PMID: 9166555

8

Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.

D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein A, Coleman CN. D'Amico AV, et al. Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1053-8. doi: 10.1016/s0360-3016(96)00633-5. Int J Radiat Oncol Biol Phys. 1997. PMID: 9169812 Free article.

9

Outcome based staging for clinically localized adenocarcinoma of the prostate.

D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A. D'Amico AV, et al. J Urol. 1997 Oct;158(4):1422-6. J Urol. 1997. PMID: 9302135

10

Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.

D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Wein A, Tomaszewski JE, Coleman CN. D'Amico AV, et al. Cancer. 1998 Jan 15;82(2):334-41. doi: 10.1002/(sici)1097-0142(19980115)82:2<342::aid-cncr14>3.0.co;2-z. Cancer. 1998. PMID: 9445191

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

505 results

Search Page

Filters